<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC6968813\results\search\testTrace\results.xml">
  <result pre="outcomes with reductions in mortality have been reported with concomitant" exact="treatment" post="containing antiretroviral drugs for the HIV component and antitubercular"/>
  <result pre="and antitubercular drugs for the DR-TB component. Early and rapid" exact="diagnosis" post="with genotypic tests, prompt treatment with appropriate regimens based"/>
  <result pre="DR-TB component. Early and rapid diagnosis with genotypic tests, prompt" exact="treatment" post="with appropriate regimens based on drug-susceptibility testing, preference for"/>
  <result pre="considered a significant threat with challenging management. Proper adherence to" exact="treatment" post="remains an issue, due to higher pill burden, overlapping"/>
  <result pre="potential drug interactions, ADRs and monitoring requirements in the concomitant" exact="treatment" post="of M/XDR-TB and HIV, and infection-control implications in the"/>
  <result pre="Among 30 high-burden countries with TB and HIV coinfection, HIV" exact="infection" post="has been detected in 70% of patients with TB."/>
  <result pre="as R and ethambutol (E), leading to drug resistance and" exact="treatment" post="failure; early reactivation of an infection due to increased"/>
  <result pre="to drug resistance and treatment failure; early reactivation of an" exact="infection" post="due to increased vulnerability in an immunocompromised state acquired"/>
  <result pre="primary reason for the lack of data is that HIV" exact="infection" post="and anti-TB drug-susceptibility testing (DST) are not adequately accessible"/>
  <result pre="lack of data is that HIV infection and anti-TB drug-susceptibility" exact="testing" post="(DST) are not adequately accessible for joint surveillance under"/>
  <result pre="and drug resistance. There was a lower association for DR-TB" exact="infection" post="in PLHIV from the US. Additional information on overlapping"/>
  <result pre="confined to high-risk groups, even in countries showing a high" exact="prevalence" post="of MDR-TB along with an emerging HIV epidemic. Detailed"/>
  <result pre="drug resistance from 2007 to 2011 in PLHIV, with average" exact="prevalence" post="of 36.1% for both new and retreatment cases, although"/>
  <result pre="increase in the burden of TB and HIV coinfection.8 The" exact="prevalence" post="of MDR-TB was 20% higher in HIV-positive patients than"/>
  <result pre="a stronger association than community- or population-based studies. With high" exact="prevalence" post="of HIV seropositivity and M/XDR-TB, countries from sub-Saharan African"/>
  <result pre="from sub-Saharan African and Asia-Pacific regions have reported very low" exact="prevalence" post="of coinfection.9 Factors responsible for underestimation of prevalence were"/>
  <result pre="very low prevalence of coinfection.9 Factors responsible for underestimation of" exact="prevalence" post="were delay in diagnosis, increased susceptibility to infection or"/>
  <result pre="underestimation of prevalence were delay in diagnosis, increased susceptibility to" exact="infection" post="or progression of disease, and lack of infrastructure. The"/>
  <result pre="or outbreaks.7,24â€&quot;28 TB in PLHIV is mostly smear-negative, and delayed" exact="diagnosis" post="due to lack of rapid diagnostic tests and appropriate"/>
  <result pre="diagnosis due to lack of rapid diagnostic tests and appropriate" exact="treatment" post="has led to high mortality in PLHIV. Epidemics of"/>
  <result pre="Eastern European regions, over the last decade, leading to poor" exact="treatment" post="outcomes and high mortality.29â€&quot;31 The epidemic of HIV infection"/>
  <result pre="poor treatment outcomes and high mortality.29â€&quot;31 The epidemic of HIV" exact="infection" post="in the European region is concentrated within high-risk groups,"/>
  <result pre="Other factors responsible for acquired drug resistance are suboptimal anti-TB" exact="treatment" post="due to poor maintenance of quality of drugs; prescription"/>
  <result pre="patients, due to either increased hospitalization in settings with poor" exact="infection" post="control or association with colleagues with M/XDR-TB, particularly in"/>
  <result pre="with additional resistance to FQs or SLIDs, and XDR-TB, with" exact="prevalence" post="rates of 38%, 21%, and 6%, respectively, among HIV-infected"/>
  <result pre="mono-DR-TB and poly-DR-TB were 21% and 12%, respectively. Further, the" exact="prevalence" post="rate of MDR-TB was 11.4% among new TB cases"/>
  <result pre="Clinical Features and Diagnosis of M/XDR-TB in PLHIV An accurate" exact="diagnosis" post="of DS-TB as well as DR-TB in HIV-infected people"/>
  <result pre="at increased risk of M/XDR-TB, such as those in whom" exact="treatment" post="has failed or who are contacts of M/XDR-TB cases."/>
  <result pre="Genotypic tests have been endorsed by the WHO, facilitating prompt" exact="diagnosis" post="of M/XDR-TB.47 The CBNAAT can establish diagnoses in smear-positive"/>
  <result pre="LiPAs to first- and second-line anti-TB drugs to facilitate early" exact="diagnosis" post="with universal DST and initiation of appropriate treatment. Newer"/>
  <result pre="The M/XDR-TB component should be treated with conventional regimens, with" exact="treatment" post="duration of at least 18â€&quot;20 months containing a combination"/>
  <result pre="include newer drugs, such as Bdq and Dlm.1,51,56 Duration of" exact="treatment" post="has to be decided on the basis of treatment"/>
  <result pre="of treatment has to be decided on the basis of" exact="treatment" post="response, and should be continued for 15â€&quot;17 months after"/>
  <result pre="expensive, and more toxic, leading to poor adherence and making" exact="treatment" post="challenging for M/XDR-TB and HIV coinfection. The WHO has"/>
  <result pre="WHO has recommended a standardized shorter and economical 9â€&quot;12 months" exact="treatment" post="regimen for MDRâ€‘TB cases containing a combination of second-line"/>
  <result pre="cases containing a combination of second-line anti-TB drugs to improve" exact="treatment" post="outcomes of MDRâ€‘TB.1,51,58 The currently recommended shorter MDR-TB regimen"/>
  <result pre="Cfz, E, and Z. These are indicated only if the" exact="treatment" post="history does not contain exposure to second-line anti-TB drugs"/>
  <result pre="been reclassified by the WHO based on emerging evidence regarding" exact="treatment" post="outcome and profile of ADRs, especially with linezolid (Lzd),"/>
  <result pre="on newer shorter regimens are ongoing in order to improve" exact="treatment" post="outcomes. These trials are conducted by Research Excellence to"/>
  <result pre="as well in addition to DR-TB, facilitating approach of universal" exact="treatment" post="in subsequent years. These regimens are currently in phase"/>
  <result pre="phase 3 trials for further validation. The approach of universal" exact="treatment" post="might have potential advantages in PLHIV such as reduction"/>
  <result pre="1 Grouping of antitubercular drugs for design of regimens for" exact="treatment" post="of drug-resistant tuberculosis WHO Guidelines 201456 WHO Guidelines 201651"/>
  <result pre="2 Grouping of antiretroviral drugs for design of regimens for" exact="treatment" post="of HIV Group Antiretroviral drugs Nucleoside reverse-transcriptase inhibitors Zidovudine"/>
  <result pre="any of these drugs. Life-long uninterrupted ART remains the cornerstone" exact="treatment" post="for the HIV component. It contains at least three"/>
  <result pre="be implemented at a programmatic level in view of early" exact="detection" post="of probable resistance to ART drugs, including integrase inhibitors,"/>
  <result pre="combined with ART; some toxicities are common to both anti-TB" exact="treatment" post="and ART, which may result in additive rates of"/>
  <result pre="with M/XDR-TB Concomitant use of ART with an appropriate anti-TB" exact="treatment" post="improves survival for both DS-TB and DR-TB. However, the"/>
  <result pre="the probability of overlapping or additive ADRs could compromise the" exact="treatment" post="of HIV or M/XDR-TB if both are started simultaneously."/>
  <result pre="introduction of ART in newly diagnosed HIV patients receiving DR-TB" exact="treatment" post="remains undefined. ART should be initiated in all TB"/>
  <result pre="immediately introduced within the first 2 weeks of initiating TB" exact="treatment" post="when there is advanced disease with CD4 count &amp;lt;50/cm3."/>
  <result pre="drug interactions becomes minimal. They are prescribed only in the" exact="treatment" post="of R-sensitive poly-DR-TB and mono-DR-TB. Relevant drugâ€&quot;drug interactions are"/>
  <result pre="modify doses of Eto/Pto and certain ART drugs during concomitant" exact="treatment" post="has not been clearly specified. Clr acts as a"/>
  <result pre="significant worsening of peripheral neuropathy associated primarily with either HIV" exact="infection" post="or combination with stavudine (d4T) and also bone-marrow depression"/>
  <result pre="consistent virological suppression, and immunological recovery is required.60 Integrated home-based" exact="treatment" post="can also be an effective alternative strategy to improve"/>
  <result pre="may require additional socioeconomic, nutritional, and psychosocial support to improve" exact="treatment" post="outcomes. Collaborative TB/HIV Activities The WHO has endorsed certain"/>
  <result pre="and increase the success of M/XDR-TB and HIV control and" exact="treatment" post="activities. The management of TB in PLHIV relies on"/>
  <result pre="as the â€œthree Isâ€�: intensified case-finding, isoniazid preventive therapy, and" exact="infection" post="control. The Joint United Nations Programme on HIV/AIDS (UNAIDS)"/>
  <result pre="HIV Testing and Counseling in All TB Suspects Voluntary HIV" exact="testing" post="and counseling is recommended for all TB suspects with"/>
  <result pre="and Counseling in All TB Suspects Voluntary HIV testing and" exact="counseling" post="is recommended for all TB suspects with clinical symptoms,"/>
  <result pre="HIV coinfection. Diagnosed TB patients showing relapse or failure to" exact="treatment" post="should also be screened for HIV coinfection. Testing for"/>
  <result pre="if available. This will avoid referring patients elsewhere for HIV" exact="testing" post="and counseling to prevent attrition or loss to follow-up."/>
  <result pre="This will avoid referring patients elsewhere for HIV testing and" exact="counseling" post="to prevent attrition or loss to follow-up. Standard Protocols"/>
  <result pre="New protocols need to be devised, especially for enhancing the" exact="diagnosis" post="and treatment of PLHIV with smear-negative pulmonary and extrapulmonary"/>
  <result pre="need to be devised, especially for enhancing the diagnosis and" exact="treatment" post="of PLHIV with smear-negative pulmonary and extrapulmonary TB. Mycobacterial"/>
  <result pre="apart from smear microscopy are recommended to help in the" exact="diagnosis" post="of sputum smearâ€&quot;negative and extrapulmonary TB. Smear microscopy carries"/>
  <result pre="be considered up front in the protocol for establishing rapid" exact="diagnosis" post="by detecting R resistance.56 Only Ethiopia and South Africa"/>
  <result pre="care.76 Nearly 500,200 PLHIV have been offered the CBNAAT for" exact="diagnosis" post="in India.5 A study reported that GeneXpert MTB/RIF utilization"/>
  <result pre="followed by initiation of ART can reduce mortality and improve" exact="treatment" post="outcomes. Although performing DST for all DS-TB and DR-TB"/>
  <result pre="burden of M/XDR-TB and HIV epidemics. Figure 1 Algorithm for" exact="diagnosis" post="of drug-resistant tuberculosis in people living with HIV. Prompt"/>
  <result pre="Specialized Team Team members should be well trained in providing" exact="treatment" post="to patients with M/XDR-TB and HIV coinfection. Strict monitoring"/>
  <result pre="to patients with M/XDR-TB and HIV coinfection. Strict monitoring of" exact="treatment" post="response, occurrence of potential additive ADRs, and nutritional status"/>
  <result pre="leading to decreased efficacy of anti-TB drugs. Additive ADRs affect" exact="treatment" post="adherence, leading to more frequent visits. Therefore, patients should"/>
  <result pre="break the chain of transmission. Various measures, such as rapid" exact="detection" post="with genotypic tests, universal DST to prescribe appropriate individualized"/>
  <result pre="with newer drugs to improve adherence, decentralized or patient-centric approaches," exact="infection" post="control, and preventive treatment for DR-TB contacts, have been"/>
  <result pre="improve adherence, decentralized or patient-centric approaches, infection control, and preventive" exact="treatment" post="for DR-TB contacts, have been emphasized to drastically reduce"/>
  <result pre="also essential to reduce the burden of coinfection. Ideally, routine" exact="diagnosis" post="should be scaled up at the programmatic level for"/>
  <result pre="affected, sample size, extent of disease burden, and quality of" exact="treatment" post="services offered. Shorter regimens might show promising results, particularly"/>
  <result pre="delayed management and poor adherence to treatment. Adequate adherence to" exact="treatment" post="remains challenging, because of the long and difficult treatment"/>
  <result pre="to treatment remains challenging, because of the long and difficult" exact="treatment" post="associated with M/XDR-TB and HIV coinfection; additional comorbid illnesses,"/>
  <result pre="showed that the incidence of TB-IRIS in PLHIV on ART" exact="treatment" post="was 15.7% (95% CI 9.7%â€&quot;24.5%), with mortality of 3.2%"/>
  <result pre="form is an inflammatory manifestation of an apparently asymptomatic subclinical" exact="infection" post="occurring after initiation of ART, resulting in clinical worsening."/>
  <result pre="reasons. It is important to note that IRIS is a" exact="diagnosis" post="of exclusion. Clinical suspicion of IRIS is high, provided"/>
  <result pre="are ruled out. Other causes mimicking TB-IRIS include superimposed infections," exact="treatment" post="failure, and relapse and progression of disease due to"/>
  <result pre="clinical profile, extent of disease, and site of involvement. Various" exact="treatment" post="modalities have been used depending on the severity. These"/>
  <result pre="few cases. Chemoprophylaxis of Drug-Resistant Tuberculosis PLHIV are vulnerable to" exact="infection" post="with TB bacillus, including DR ones. The annual risk"/>
  <result pre="bacillus, including DR ones. The annual risk of developing TB" exact="infection" post="in the HIV-infected population is ten times that of"/>
  <result pre="uninfected.98,99 Screening is required for ruling out not only active" exact="infection" post="but also latent infection. Chemoprophylaxis is indicated if the"/>
  <result pre="but also latent infection. Chemoprophylaxis is indicated if the latent" exact="infection" post="is detected by immunologic testing, such as tuberculin skin"/>
  <result pre="chemoprophylaxis has been reported to reduce the risk of TB" exact="infection" post="by 35%, with larger benefit in the skin testâ€&quot;positive"/>
  <result pre="in preventing active disease among people with or without HIV" exact="infection" post="havin contacts with M/XDR-TB patients.103,104 People in whom latent"/>
  <result pre="infection havin contacts with M/XDR-TB patients.103,104 People in whom latent" exact="infection" post="is diagnosed are often infected with the same strain"/>
  <result pre="infected with the same strain as the index case. Prompt" exact="treatment" post="of the index case with DR-TB should be the"/>
  <result pre="should be the priority. If contact is asymptomatic, no prophylactic" exact="treatment" post="is recommended, and the patient should be placed under"/>
  <result pre="progression of disease. If the contact is symptomatic, presumptive TB" exact="infection" post="should be suspected and investigated further with the CBNAAT"/>
  <result pre="further with the CBNAAT or appropriate investigation. Prompt initiation of" exact="treatment" post="with a regimen designed to treat the index case"/>
  <result pre="index case of DR-TB. The reduction of risk of developing" exact="infection" post="has been reported to be 37%â€&quot;90%.100,101,104 These regimens are"/>
  <result pre="(PHOENIXMDR-TB trial).78 National programs should emphasize chemoprophylaxis in preventing latent" exact="infection" post="among HIV-endemic areas where the probability of DR-TB coinfection"/>
  <result pre="to prove the efficacy of chemoprophylaxis in the prevention of" exact="infection" post="in PLHIV with contacts with M/XDR-TB. Infection Control Infection"/>
  <result pre="with or without HIV coinfection. It restricts the transmission of" exact="infection" post="from patients to high-risk groups, especially health-care workers. There"/>
  <result pre="DR strains, although evidence is sparse. Such factors as delayed" exact="diagnosis" post="of M/XDR-TB causing prolonged duration of infectiousness leading to"/>
  <result pre="and HIV are responsible for nosocomial transmission. These practices enhance" exact="infection" post="epidemics or outbreaks, particularly in HIV-endemic settings. Implementation of"/>
  <result pre="health centers or hospitals significantly reduces nosocomial transmission.106 Interventions for" exact="infection" post="control should be adopted at three levels: administrative, environmental/engineering,"/>
  <result pre="trials, so the existing recommendations are based on consensus. Community-based" exact="treatment" post="programs should implement these measures on a larger scale."/>
  <result pre="a growing problem in many parts of the world. Rapid" exact="diagnosis" post="with genotypic tests, prompt treatment with appropriate regimens, including"/>
  <result pre="parts of the world. Rapid diagnosis with genotypic tests, prompt" exact="treatment" post="with appropriate regimens, including shorter regimens fortified with newer"/>
  <result pre="Infect Dis. 2008;8(4):233â€&quot;243. doi:10.1016/S1473-3099(07)70291-818201929 3.WellsCD, CegielskiJP, NelsonLJ, et al. HIV" exact="infection" post="and multi-drug resistant tuberculosis: the perfect storm. J Infect"/>
  <result pre="from:https://www.who.int/tb/publications/global_report/en/. Accessed 2810 2019. 6.SuchindranS, BrouwerES, Van RieA. Is HIV" exact="infection" post="a risk factor for multi-drug-resistant tuberculosis? A systematic review."/>
  <result pre="AchenbachC, TaiwoB, et al. Evaluation of Gene Xpert for routine" exact="diagnosis" post="of HIV-associated tuberculosis in Nigeria: a prospective cohort study."/>
  <result pre="Catching the missing million: experiences in enhancing TB &amp;amp; DR-TB" exact="detection" post="by providing upfront Xpert MTB/RIF testing for people living"/>
  <result pre="enhancing TB &amp;amp; DR-TB detection by providing upfront Xpert MTB/RIF" exact="testing" post="for people living with HIV in India. PLoS One."/>
  <result pre="Med. 2011;8(7):e1001067. doi:10.1371/journal.pmed.100106721818180 15.SaldanhaN, RunwalK, GhanekarC, GaikwadS, SaneS, PujariS. High" exact="prevalence" post="of multi drug resistant tuberculosis in people living with"/>
  <result pre="ChondeTM, GrafP, RiederHL. An epidemiological study of tuberculosis and HIV" exact="infection" post="in Tanzania, 1991â€&quot;1993. AIDS. 1996;10(3):299â€&quot;309. doi:10.1097/00002030-199603000-000098882670 17.KenyonTA, MwasekagaMJ, HuebnerR,"/>
  <result pre="of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus" exact="infection" post="in an urban hospital: epidemiologic and restriction fragment length"/>
  <result pre="doi:10.1371/journal.pone.000437019190774 45.CainKP, McCarthyKD, HeiligCM, et al. An algorithm for tuberculosis" exact="screening" post="and diagnosis in people with HIV. N Engl J"/>
  <result pre="McCarthyKD, HeiligCM, et al. An algorithm for tuberculosis screening and" exact="diagnosis" post="in people with HIV. N Engl J Med. 2010;362:707â€&quot;716."/>
  <result pre="Microbiol Rev. 2011;24(2):351â€&quot;376. doi:10.1128/CMR.00042-1021482729 47.ParsonsLM, SomoskÃ¶viA, GutierrezC, et al. Laboratory" exact="diagnosis" post="of tuberculosis in resource-poor countries: challenges and opportunities. Clin"/>
  <result pre="opportunities. Clin Microbiol Rev. 2011;24(2):314â€&quot;350. doi:10.1128/CMR.00059-1021482728 48.collab: WHO. Improving the" exact="diagnosis" post="and treatment of smear-negative pulmonary and extra-pulmonary tuberculosis among"/>
  <result pre="Microbiol Rev. 2011;24(2):314â€&quot;350. doi:10.1128/CMR.00059-1021482728 48.collab: WHO. Improving the diagnosis and" exact="treatment" post="of smear-negative pulmonary and extra-pulmonary tuberculosis among adults and"/>
  <result pre="from:https://www.who.int/hiv/pub/tb/pulmonary/en/. Accessed 522, 2019. 49.collab: WHO. Guidance on provider-initiated HIV" exact="testing" post="and counselling in health facilities. Geneva: World Health Organization,"/>
  <result pre="Automated real-time nucleic acid amplification technology for rapid and simultaneous" exact="detection" post="of tuberculosis and rifampicin resistance: xpert MTB/RIF assay for"/>
  <result pre="of tuberculosis and rifampicin resistance: xpert MTB/RIF assay for the" exact="diagnosis" post="of pulmonary and extra-pulmonary TB in adults and children."/>
  <result pre="2013Available from:https://apps.who.int/iris/handle/10665/112472. Accessed 525, 2019. 51.collab: World Health Organization. WHO" exact="treatment" post="guidelines for drug-resistant tuberculosis; [update 2016] (October 2016 revision)(WHO/HTM/TB/2016.04)Geneva:"/>
  <result pre="2019. 52.DormanSE, SchumacherSG, AllandD, et al. Xpert MTB/RIF Ultra for" exact="detection" post="of Mycobacterium tuberculosis and rifampicin resistance: a prospective multi-centre"/>
  <result pre="yield and prognostic value of determine TB-LAM for routine diagnostic" exact="testing" post="for tuberculosis in HIV-infected patients requiring acute hospital admission"/>
  <result pre="57.YuenCM, KurbatovaE, TupasiT, et al. Association between regimen composition and" exact="treatment" post="response in patients with multidrug-resistant tuberculosis: a prospective cohort"/>
  <result pre="doi:10.1097/FTD.000000000000010824943062 64.Oâ€™DonnellMR, PadayatchiN, DaftaryA, et al. Antiretroviral switching and bedaquiline" exact="treatment" post="of drug-resistant tuberculosis HIV co-infection. Lancet HIV. 2019;6(3):e201â€&quot;e204. doi:10.1016/S2352-3018(19)30035-930846058"/>
  <result pre="FirnhaberC, BerhanuR, et al. Adverse drug reactions during drug-resistant TB" exact="treatment" post="in high HIV prevalence settings: a systematic review and"/>
  <result pre="Adverse drug reactions during drug-resistant TB treatment in high HIV" exact="prevalence" post="settings: a systematic review and meta-analysis. J Antimicrob Chemother."/>
  <result pre="70.WuS, ZhangY, SunF, et al. Adverse events associated with the" exact="treatment" post="of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Am"/>
  <result pre="TB strategy. Lancet. 2015;385(9979):1799â€&quot;1801. doi:10.1016/S0140-6736(15)60570-025814376 75.collab: UNAIDS. 90â€&quot;90â€&quot;90: an ambitious" exact="treatment" post="target to help end the AIDS epidemic. JC; 2014:"/>
  <result pre="Dickson-HallL, NdjekaN, et al. Delays and loss to follow-up before" exact="treatment" post="of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in"/>
  <result pre="MlisanaK, et al. Improved survival and cure rates with concurrent" exact="treatment" post="for MDR-TB/HIV co-infection in South Africa. Clin Infect Dis."/>
  <result pre="Infect Dis. 2018;66(8):1246â€&quot;1253. doi:10.1093/cid/cix112529293906 83.ShinSS, ModongoC, BoydR, et al. High" exact="treatment" post="success rates among HIV infected multidrug-resistant tuberculosis patients after"/>
  <result pre="doi:10.1097/QAI.000000000000116927552155 84.AhujaSD, AshkinD, AvendanoM, et al. Multidrug resistant pulmonary tuberculosis" exact="treatment" post="regimens and patient outcomes: an individual patient data meta-analysis"/>
  <result pre="PLoS Med. 2012;9(8):e1001300. doi:10.1371/journal.pmed.100130022952439 85.BrustJC, GandhiNR, CarraraH, OsburnG, PadayatchiN. High" exact="treatment" post="failure and default rates for patients with multidrug-resistant tuberculosis"/>
  <result pre="rifampicin-resistant tuberculosis in Khayelitsha, South Africa: impact on mortality and" exact="treatment" post="success. PLoS One. 2015;10(11):e0142873. doi:10.1371/journal.pone.014287326555134 87.Oâ€™DonnellMR, PadayatchiN, KvasnovskyC, WernerL,"/>
  <result pre="Infect Dis. 2013;19(3):416â€&quot;424. doi:10.3201/eid1903.12099823622055 88.CarlucciJG, BlevinsPM, KippAM, et al. Tuberculosis" exact="treatment" post="outcomes among HIV/TB Co-infected Children in the International Epidemiology"/>
  <result pre="2012;16(1):90â€&quot;97. doi:10.5588/ijtld.11.015322236852 93.AzeezA, NdegeJ, MutambayiR. Associated factors with unsuccessful tuberculosis" exact="treatment" post="outcomes among tuberculosis/HIV co-infected patients with drug-resistant tuberculosis. Int"/>
  <result pre="reconstitution disease: incidence, risk factors and impact in an antiretroviral" exact="treatment" post="service in South Africa. AIDS. 2007;21(3):335â€&quot;341. doi:10.1097/QAD.0b013e328011efac17255740 96.NavasE, MartÃ­n-DÃ¡vilaP,"/>
  <result pre="and meta-analysis. Lancet Infect Dis. 2010;10(4):251â€&quot;261. doi:10.1016/S1473-3099(10)70026-820334848 98.HorsburghCRJr.Priorities for the" exact="treatment" post="of latent tuberculosis infection in the United States. N"/>
  <result pre="Dis. 2010;10(4):251â€&quot;261. doi:10.1016/S1473-3099(10)70026-820334848 98.HorsburghCRJr.Priorities for the treatment of latent tuberculosis" exact="infection" post="in the United States. N Engl J Med. 2004;350(20):2060â€&quot;2067."/>
  <result pre="doi:10.1056/NEJMsa03166715141044 99.DurovniB, SaraceniV, MoultonLH, et al. Effect of improved tuberculosis" exact="screening" post="and isoniazid preventive therapy on incidence of tuberculosis and"/>
  <result pre="2006;19(2):CD005435. 102.MarksSM, MaseSR, MorrisSB. Systematic review, meta-analysis, and cost-effectiveness of" exact="treatment" post="of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis."/>
  <result pre="Lancet. 2007;370(9597):1500â€&quot;1507. doi:10.1016/S0140-6736(07)61636-517964351 107.ShinS, FurinJ, BayonaJ, MateK, KimJY, FarmerP. Community-based" exact="treatment" post="of multidrug-resistant tuberculosis in Lima, Peru: 7 years of"/>
 </snippets>
</snippetsTree>
